Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.~2. The participant signs and dates a written informed consent form prior to the initiation of any study procedures.~3. The participant has essential hypertension.~4. The participant has an office sitting systolic blood pressure (SBP) of \<180 mmHg and office sitting diastolic blood pressure (DBP) of \< 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of \< 160 mmHg and an office sitting DBP of \< 100 mmHg.~5. The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either:~   * Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)\*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg~  * Participants with concurrent diabetes mellitus or CKD\*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg.~     * Estimate glomerular filtration rate according to creatinine (eGFRcreat) of \<60 mL/min/1.73 m\^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator.~6. The participant has an office sitting SBP of \< 160 mmHg and office sitting DBP of \< 100 mmHg at the end of the run-in period (Week 0).~7. The participant is male or female, aged 20 years or older at the time of providing informed consent.~8. The participant is an outpatient.~9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study.~Exclusion Criteria:~1. The participant has received any study drugs within 12 weeks prior to the start of the run-in period.~2. The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period.~3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress.~4. The participant requires taking prohibited concomitant drugs during the study.~5. The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH.~6. The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication.~7. The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH.~8. The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period.~9. The participant has secondary or malignant hypertension.~10. The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4).~11. The participant has apparent white coat hypertension or exhibits a white coat effect.~12. . The participant has a day-night reversed lifestyle, such as those working during the night.~13. The participant has sleep apnea syndrome requiring treatment.~14. The participant has any of the following cardiovascular diseases:~    * Cardiac disease: Myocardial infarction\*, coronary arterial revascularization\*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia~   * Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage\*, transient ischemic attack\*~   * Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm~   * Advanced hypertensive retinopathy: With bleeding or exudate/papilledema\*\* \* Occurring or performed within 24 weeks of the start of the run-in period \*\* Observed within 24 weeks of the start of the run-in period~15. The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN).~16. The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period \< 30 mL/minute/1.73 m\^2).~17. The participant's body fluid sodium or potassium level is markedly low\* or high\*.~    \*Based on normal ranges~18. The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment.~19. The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period).~20. The participant has a malignant tumor.~21. If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study.~22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period.~23. The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-536TCH (Type: EXPERIMENTAL): For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast.

Based on this trial design, predict the completion outcome and termination type (if applicable).